Why Complicated UTIs Are Hard to Treat

Beyond Simple Bladder Infections

Uncomplicated bladder infections usually respond to standard oral antibiotics. Complicated UTIs are different. They involve the upper urinary tract (pyelonephritis), occur in people with anatomical or functional urinary problems, or develop in those with catheters or recent urologic procedures. These infections can become severe and may spread to the bloodstream, which is why they are usually managed with careful culture-guided therapy.

Resistance Limits Choices

Many complicated UTIs are caused by gram-negative bacteria, especially Escherichia coli and Klebsiella pneumoniae. Some of these organisms produce ESBLs or AmpC enzymes, which inactivate many common beta-lactam antibiotics. When standard options fail, clinicians may turn to broader agents, including carbapenems. Carbapenems are valuable for the most serious resistant infections, so clinicians look for effective alternatives that help preserve them.

Why Protected Combinations Matter

A beta-lactamase inhibitor paired with an established antibiotic can restore activity against some resistant organisms. This is the strategy behind Exblifep: keep a proven drug in the cephalosporin class and protect it from the enzymes that normally defeat it.

Who Is Most Affected

Women account for most uncomplicated UTIs, but complicated UTIs affect both sexes. Risk factors include urinary catheters, kidney stones, obstruction, diabetes, pregnancy, recent hospitalization, and prior antibiotic exposure. Older adults and people with weakened immune systems can develop serious infections more quickly.

Key Takeaways

• Exblifep (cefepime/enmetazobactam) received FDA approval on February 22, 2024, for adults with complicated UTI, including pyelonephritis, caused by designated susceptible organisms.
• Cefepime is a fourth-generation cephalosporin; enmetazobactam is a beta-lactamase inhibitor that protects cefepime from ESBL and some AmpC enzymes.
• In the ALLIUM trial, 79.1 percent of cefepime/enmetazobactam patients achieved clinical cure and microbiological eradication, compared with 58.9 percent receiving piperacillin/tazobactam.
• Clinical cure rates were similar between arms (92.5 percent vs 88.9 percent). The difference came mainly from microbiological eradication (82.9 percent vs 64.9 percent).
• In the ESBL-producing subgroup, the composite outcome was 73.7 percent versus 51.5 percent, but this subgroup was small.
• The labeled regimen is an IV infusion over 2 hours every 8 hours, with adjustments for kidney function.
• The label directs use only for infections proven or strongly suspected to be caused by susceptible bacteria.

What Is Exblifep

Brand and Generic Names

Exblifep is the brand name for cefepime and enmetazobactam, marketed in the United States by Allecra Therapeutics. The product is supplied for intravenous infusion, and the two components are provided together in a single product.

Drug Class

Cefepime belongs to the cephalosporin family of beta-lactam antibiotics and has been used for serious infections for decades. Enmetazobactam is a beta-lactamase inhibitor. Inhibitors like this have little antibacterial activity on their own; their role is to protect the partner antibiotic from enzymatic destruction.

Why a Combination Matters

Cefepime alone can be destroyed by ESBL and AmpC enzymes. Adding enmetazobactam helps keep cefepime active against some of those organisms, which extends the usefulness of an established drug without requiring an entirely new antibiotic class.

Dosage Form

Exblifep is an injection given by infusion. It is not a tablet, so it is used in hospitals, infusion centers, or other settings where IV therapy is managed by trained staff.

FDA Approval: February 22, 2024

The Approval Decision

The FDA approved Exblifep on February 22, 2024. Allecra Therapeutics announced the approval in a news release dated February 27, 2024, which is why some articles use that later date. The approval covers adults aged 18 and older with cUTI, including pyelonephritis, caused by designated susceptible microorganisms.

Marketing Exclusivity

The FDA also granted a five-year marketing exclusivity extension under the Generating Antibiotic Incentives Now (GAIN) Act. This incentive is designed to encourage development of new antibiotics for serious infections, a market that has historically been unattractive to developers.

Labeling Boundaries

The label is limited to cUTI. It is not approved for bloodstream infections, uncomplicated UTIs, or children. Treatment outside the labeled use is a clinical decision for the treating team, based on the infection, the patient, and local resistance patterns.

Why the Publication Date Matters

The primary ALLIUM results were published in JAMA in 2022, before the FDA decision. Readers who see different dates in different articles are usually seeing the approval date, the company announcement date, or the publication date. The approval date is February 22, 2024.

How the Combination Works

Cell Wall Disruption

Cefepime binds to penicillin-binding proteins in the bacterial cell wall. Interfering with cell wall construction weakens the bacterium until it dies. This is the same general mechanism as other beta-lactam antibiotics.

Enzyme Protection

Many gram-negative bacteria produce beta-lactamase enzymes that break open the beta-lactam ring of antibiotics such as cefepime. Enmetazobactam binds these enzymes and blocks their activity, allowing cefepime to reach its targets.

Synergy in Practice

The combination works best when the organism's main resistance mechanism is one that enmetazobactam can inhibit. Laboratory testing is what determines whether a particular isolate is susceptible, so the drug's general reputation does not replace a specific result.

Cefepime: The Partner Antibiotic

History and Use

Cefepime was approved in the United States in 1996 and has been used for pneumonia, febrile neutropenia, skin infections, and complicated urinary infections. Its spectrum includes many gram-negative organisms and some gram-positive organisms.

Why Cefepime Alone Is Not Enough

Organisms that produce ESBL or AmpC enzymes can inactivate cefepime. As these organisms have spread in community and hospital settings, cefepime alone has become less reliable for empiric therapy in some regions. Adding a protective inhibitor is one way to address that gap.

Known Safety Profile

Because cefepime has a long history of use, its general side effects and warnings are well characterized. The most important is neurotoxicity in patients with reduced kidney function, discussed below.

What Enmetazobactam Does

Targets

Enmetazobactam is designed to inhibit ESBL enzymes and some AmpC beta-lactamases. These enzymes are common in urinary pathogens and are a major reason beta-lactams fail in complicated UTIs.

How Inhibition Helps

By binding the enzyme, enmetazobactam reduces the amount of cefepime that gets destroyed. The partner antibiotic then has the opportunity to reach penicillin-binding proteins and kill the bacterium.

Limits

Enmetazobactam does not overcome every resistance mechanism. Organisms with certain carbapenemases or other enzymes may remain resistant. This is one reason the label requires that the infection be caused by a susceptible organism.

Approved Use and Labeling Limits

Who Is Eligible

The approved population is adults aged 18 and older with cUTI or acute pyelonephritis caused by designated susceptible organisms. Common gram-negative urinary pathogens named in label summaries include Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis. The complete organism list should be checked in the current prescribing information.

Stewardship Language

The label says the drug should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. This language reflects the goal of preserving the drug's usefulness for patients who need it.

Not Approved For

The FDA did not approve Exblifep for bloodstream infections as a standalone indication, uncomplicated UTIs, or children. Decisions outside those labels rest with the treating clinician.

The ALLIUM Trial: Design

Overview

ALLIUM was a phase 3, randomized, controlled, double-blind, multinational trial. Adults with cUTI or acute pyelonephritis were randomly assigned in a 1:1 ratio to receive cefepime/enmetazobactam or piperacillin/tazobactam, a standard comparator for serious gram-negative infections. The trial is registered as NCT03687255.

Treatment Arms

Patients in the cefepime/enmetazobactam arm received 2 g of cefepime with 0.5 g of enmetazobactam. Patients in the comparator arm received 4 g of piperacillin with 0.5 g of tazobactam. Both regimens were given every 8 hours by 2-hour infusion for 7 days, with up to 14 days for patients with a positive blood culture at baseline.

Population

The published analysis includes 1,034 patients randomized, with 520 assigned to cefepime/enmetazobactam and 521 to piperacillin/tazobactam. Participants had clinical signs of cUTI or acute pyelonephritis caused by gram-negative urinary pathogens. Enrollment across many sites in many countries helps show that results are not limited to a single setting.

Blinding and Randomization

The study was double-blind, meaning neither the patient nor the investigator knew which drug was being given. Randomization reduces selection bias, so the two groups start out comparable.

Primary Outcome

The primary outcome was a composite of clinical cure and microbiological eradication at the test-of-cure visit. Clinical cure means symptom resolution. Microbiological eradication means the baseline pathogen was reduced below the defined threshold in urine. Requiring both makes the endpoint a demanding measure of success.

The ALLIUM Trial: Results

Primary Analysis

In the primary analysis, 273 of 345 patients (79.1 percent) receiving cefepime/enmetazobactam achieved the composite outcome, compared with 196 of 333 patients (58.9 percent) receiving piperacillin/tazobactam. The adjusted difference was 21.2 percentage points, with a 95 percent confidence interval of 14.3 to 27.9.

Noninferiority and Superiority

The difference met the prespecified noninferiority margin of negative 10 percentage points. It also met the prespecified criterion for superiority in favor of cefepime/enmetazobactam. A noninferiority margin sets how much worse a new drug can be before it fails the comparison, so meeting it here means the new drug was not meaningfully inferior.

Summary Table

Safety in the Trial

Published summaries described a comparable safety profile between the two arms. Consistent with the label, the combination was associated with the cefepime-class warnings that clinicians monitor, including hypersensitivity, neurologic effects, and C. difficile infection.

Clinical Cure vs Microbiological Eradication

Two Different Questions

Clinical cure asks whether symptoms resolved. Microbiological eradication asks whether the bacteria were cleared from the urine. A patient can feel better while bacteria remain, and bacteria can be cleared while symptoms linger for a time.

Where the Difference Came From

Clinical cure rates were close: 92.5 percent with the combination and 88.9 percent with piperacillin/tazobactam. The larger gap was in microbiological eradication, at 82.9 percent versus 64.9 percent. Much of the composite advantage therefore reflects better bacterial clearance, which fits the activity of a protected beta-lactam against resistant organisms.

Why This Matters for Patients

Clearing the bacteria matters because incomplete eradication can lead to relapse or recurrence. A treatment that improves microbiological clearance may lower the chance that the infection returns, though long-term recurrence data should be read with care.

ESBL Subgroup Findings

The Subgroup

About one-fifth of the enrolled patients had ESBL-producing baseline pathogens. Within this subgroup, 73.7 percent of patients receiving cefepime/enmetazobactam achieved the composite outcome (56 of 76), compared with 51.5 percent receiving piperacillin/tazobactam (34 of 66).

Why It Is Encouraging

ESBL-producing organisms are among the most important resistant uropathogens. Results suggesting better outcomes in this group are consistent with the drug's design, and they are the reason the combination is discussed as a potential option for resistant infections.

Why It Must Be Read Cautiously

The subgroup is small, and subgroup results can be influenced by chance. Confidence intervals in small groups are wide. The finding supports further study and clinical use with susceptibility testing, but it is not a guarantee for any individual patient.

Limits of the Evidence

Selected Populations

Trial participants are carefully screened and may differ from real-world patients who have more comorbidities, multiple medications, or different organism profiles.

Test-of-Cure Timing

The primary outcome was measured at a test-of-cure visit. Long-term outcomes, recurrence over months, and effects in populations with severe sepsis require further data.

Comparator Choice

The comparator was piperacillin/tazobactam. Results versus other standard agents, such as carbapenems, are not the same question, and clinicians consider local resistance patterns when comparing options.

Post-Approval Experience

Real-world use will reveal how the drug performs across broader populations and organisms. Surveillance and reporting help define that picture over time.

Which Bacteria It Targets

Labeled Organisms

The label lists designated susceptible gram-negative organisms for cUTI, including Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis, among others. Confirm the complete list in the current prescribing information before relying on it.

ESBL and AmpC Producers

Enmetazobactam's inhibition of ESBL and some AmpC enzymes is the basis for activity against many resistant urinary isolates. Susceptibility testing is still needed for each infection because mechanisms vary.

Limits of Activity

Organisms with resistance mechanisms outside the drug's inhibition profile may not respond. Gram-positive organisms are not the focus of this combination, and enterococci are generally not treated with cephalosporins.

Culture Matters

Urine culture before treatment identifies the organism and its susceptibility pattern. Empiric choices may be made while results are pending, then adjusted when the laboratory reports back.

Administration and Dosing

IV Infusion

Exblifep is given by intravenous infusion. In the ALLIUM trial, each dose was infused over 2 hours. Nurses and pharmacists prepare and administer the drug according to the label, and patients should report discomfort or reactions during infusion.

Labeled Dose

The trial regimen was 2 g of cefepime with 0.5 g of enmetazobactam every 8 hours. Exact dosing, infusion time, and adjustments for kidney function should be confirmed on DailyMed or in the prescribing information rather than relying on this summary.

Preparation and Compatibility

Preparation follows the label instructions. Pharmacists check compatibility with diluents and co-administered medicines. Do not combine infusions with other drugs unless the pharmacy confirms compatibility.

Missed or Delayed Doses

In hospital, nursing staff manage missed or delayed doses. Patients should not try to make up doses on their own.

Treatment Duration

Labeled Range

In the ALLIUM trial, treatment lasted 7 days, with up to 14 days for patients who had a positive blood culture at baseline. The care team sets the actual duration based on the infection's severity, response, and culture results.

Why Duration Is Individualized

A patient with uncomplicated pyelonephritis who responds quickly may need a shorter course than a patient with bacteremia or slow improvement. Longer treatment also increases exposure to side effects and resistance pressure, so the plan is kept as short as safe.

Completing Therapy

Do not stop early because symptoms improve. Ask your team when treatment is complete and whether any follow-up testing is needed.

Kidney Function and Dosing

Why Kidney Function Matters

Cefepime is cleared by the kidneys. Reduced kidney function can cause the drug to accumulate, which raises the risk of neurologic side effects. Dose adjustment for kidney function is part of safe use.

Monitoring

Clinicians check kidney function before starting therapy and monitor it during treatment, especially in older adults and people with existing kidney disease, dehydration, or sepsis.

Dialysis

People receiving dialysis need individualized dosing, typically worked out with nephrology and pharmacy teams. Timing around dialysis sessions is part of the plan.

Common Side Effects

Gastrointestinal Effects

Nausea, diarrhea, and vomiting can occur. Most are mild. Persistent or bloody diarrhea needs prompt evaluation because C. difficile infection can occur with nearly all antibiotics.

Infusion-Related Reactions

Pain, redness, or swelling at the IV site can happen. Report these to your nurse so the line can be checked and moved if needed.

Headache and Lab Changes

Headache and changes in lab tests such as liver enzymes have been reported with cephalosporin-class drugs. Your team may check labs during longer treatment.

Rash

Skin rash can occur. Mild rash may be monitored, but rash with fever, blistering, mouth sores, or facial swelling needs urgent attention.

Serious Risks and Warnings

Hypersensitivity Reactions

Serious allergic reactions, including anaphylaxis, can occur with beta-lactam antibiotics. Hives, facial swelling, trouble breathing, or fainting require emergency care. Tell your team about any past reaction to penicillins or cephalosporins before the first dose.

Neurotoxicity

Cefepime has been associated with neurotoxicity, particularly when kidney function is reduced. Symptoms can include confusion, altered mental status, seizures, or involuntary muscle movements such as myoclonus. Clinicians watch for these signs and adjust dosing.

C. difficile Infection

C. difficile can cause severe diarrhea and colitis. Any new or worsening diarrhea during or after treatment should be reported promptly.

Neurotoxicity Warning

What It Looks Like

Early signs can include confusion, restlessness, drowsiness, or changes in alertness. More serious signs include seizures or involuntary jerking. Report any change in thinking, behavior, or movement immediately.

Who Is at Higher Risk

Risk rises with reduced kidney function, older age, pre-existing brain conditions or seizure disorders, dehydration, and higher drug exposure. Correct dosing for kidney function is the main protection.

What Happens Next

If neurotoxicity is suspected, the care team reviews the dose, checks kidney function, and may change the antibiotic. Symptoms often improve after dosing is corrected or the drug is stopped.

C. difficile Warning

Why Antibiotics Raise the Risk

Antibiotics can disrupt the normal bacteria in the gut, allowing C. difficile to grow and produce toxins. Risk is present with nearly all antibacterial drugs, so it is not unique to this combination.

Recognizing It

Watch for watery diarrhea that occurs three or more times in a day, fever, abdominal pain or cramping, or blood in the stool. Report these symptoms promptly.

Treatment Differences

C. difficile infection is treated differently from the original urinary infection. Continuing the original antibiotic without evaluation can worsen it, so the care team decides on next steps after testing.

Who Should Not Receive Exblifep

Known Allergy

People with a known allergy to cefepime, enmetazobactam, or other beta-lactam antibiotics should not receive Exblifep. Your team reviews your allergy history before treatment.

Serious Beta-Lactam Reactions

A history of severe reactions to penicillins or cephalosporins requires careful individual assessment before treatment. The type and timing of the past reaction guide the decision.

Kidney Disease and Seizure History

People with significant kidney disease or a seizure disorder need careful evaluation, because both affect neurologic risk. Dose planning and monitoring become more important.

Drug Interactions

Medication Review

Give your care team a full list of medications, including prescriptions, over-the-counter products, and supplements. Pharmacists check for interactions before starting any new antibiotic.

Other Nephrotoxic Drugs

Medicines that can harm the kidneys raise concern because reduced kidney clearance increases the risk of neurotoxicity. Your team will review these in advance and may adjust the plan.

Probenecid and Other Agents

Some drugs can slow the kidney's removal of beta-lactam antibiotics. Your pharmacist will check whether any of your medicines need attention.

How Exblifep Compares With Other Options

Piperacillin/Tazobactam

Piperacillin/tazobactam was the comparator in ALLIUM and is a standard option for many serious infections. The trial showed the new combination met criteria for both noninferiority and superiority on the composite outcome.

Carbapenems

Carbapenems such as meropenem remain important for serious resistant infections. Using Exblifep where it fits may help reduce unnecessary carbapenem use, but the choice depends on culture results, severity, and clinical judgment.

Oral Options

Some complicated UTIs can be treated with oral antibiotics once the patient is stable. Your team decides between IV and oral therapy based on the infection and your response.

Older Cephalosporins

Standard cephalosporins without an inhibitor may fail against ESBL-producing organisms. Protected combinations are considered when local resistance or prior culture results point that way.

Antibiotic Stewardship

Use Only When Indicated

The label emphasizes use only for infections proven or strongly suspected to be caused by susceptible bacteria. Using a newer combination when simpler options would work increases resistance pressure across the community and hospital.

Culture First

Urine and blood cultures with susceptibility results should guide therapy. Clinicians reassess treatment as results return and narrow or switch when appropriate.

Protecting the Drug

New antibiotics are valuable only while they remain effective. Responsible use protects that value for future patients, which is one reason hospitals review prescribing patterns.

Availability and Cost

Availability

Exblifep is given in hospital and infusion settings. Availability depends on the facility and on distribution arrangements, so your care team can confirm stock.

Cost

Prices for branded IV antibiotics are high and can change. Most costs are bundled into the overall hospital stay. Ask your insurer or hospital financial counselor for current figures.

Coverage

Coverage for FDA-approved indications is generally more straightforward, but prior authorization may be required. Pharmacy staff can help with the paperwork.

Pregnancy, Breastfeeding, and Children

Pregnancy

Pregnant patients with complicated UTIs need careful evaluation because untreated infection carries risks for both mother and baby. Decisions about Exblifep in pregnancy should involve the obstetric and infectious disease teams, weighing benefit against the limited data available.

Breastfeeding

Cephalosporins pass into breast milk in small amounts. Discuss breastfeeding plans with your care team so they can weigh the benefit and any infant considerations.

Children

The FDA labeling is for adults aged 18 and older. Use in children is outside the labeled indication and requires specialist judgment and pediatric dosing.

Questions to Ask Your Care Team

• Did my urine or blood culture identify an organism susceptible to Exblifep?
• What is my dose, and how will it be adjusted for my kidney function?
• What signs of confusion or seizure should the nurses report right away?
• Are any of my current medications a concern with this drug?
• How long will I need treatment, and what follow-up testing is planned?
• When, if ever, can I switch to oral therapy?

Frequently Asked Questions

Q: What is Exblifep used for?

A: Exblifep is approved for adults with complicated urinary tract infections, including pyelonephritis, caused by designated susceptible organisms.

Q: When was it approved?

A: The FDA approved it on February 22, 2024.

Q: Is Exblifep a pill?

A: No. It is given only by IV infusion.

Q: How well did it work in the main trial?

A: In ALLIUM, 79.1 percent of patients receiving cefepime/enmetazobactam achieved clinical cure and microbiological eradication, compared with 58.9 percent receiving piperacillin/tazobactam.

Q: Does it work against ESBL bacteria?

A: Enmetazobactam is designed to inhibit ESBL enzymes, and the ESBL subgroup did better than the comparator. The subgroup was small, so susceptibility testing is needed to confirm activity against a specific organism.

Q: Can it affect my brain?

A: Cefepime can cause neurotoxicity, especially when kidney function is reduced. Report confusion, seizures, or unusual movements right away.

Q: What if I get diarrhea?

A: Tell your care team promptly. Persistent or bloody diarrhea needs evaluation, including testing for C. difficile.

Q: Why do some articles give different approval dates?

A: The FDA approved it on February 22, 2024. Some articles cite the February 27, 2024 company announcement, and the trial was published in JAMA before approval.

Medical Disclaimer

This article is for general education only and does not provide medical advice, diagnosis, or treatment. Complicated urinary tract infections can be serious and require evaluation by a qualified clinician. Do not start, stop, or change any antibiotic without guidance from your care team. For dosing, warnings, and interactions, consult the current U.S. prescribing information on DailyMed. If you have fever with chills, flank pain, confusion, seizures, or difficulty breathing, seek emergency care immediately.

Sources and Further Reading

• Kaye KS, Belley A, Barth P, et al. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial. JAMA, 2022
• U.S. FDA approval of Exblifep (cefepime/enmetazobactam), February 22, 2024
• Allecra Therapeutics news release announcing U.S. FDA approval, February 27, 2024
• Allecra Therapeutics press release on publication of final ALLIUM data in JAMA, October 2022
• Drugs.com Exblifep FDA approval history
• Exblifep U.S. Prescribing Information, including warnings on hypersensitivity, neurotoxicity, and C. difficile-associated diarrhea
• Urology Times 2024 pipeline report on the approval and GAIN Act exclusivity

This article reflects information available as of October 2026. Confirm current prescribing details with your healthcare provider and the latest FDA labeling. For more on antibiotic options, visit MyOnlineMedShop blog or contact us.